iSTAR Medical

EQT Life Sciences announced that AbbVie and iSTAR Medical entered a strategic transaction to further develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device. Deal terms include a $60 million upfront payment to iSTAR Medical.

AbbVie and iSTAR Medical announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical device. The deal includes a $60 million upfront payment to iSTAR Medical, which will continue development and commercialization up to completion of the U.S. PMA study.